18
Participants
Start Date
September 7, 2023
Primary Completion Date
December 1, 2025
Study Completion Date
December 31, 2025
IMC002 injection
"three different IMC002 Doses will be escalated in 3+3 design"
RECRUITING
Chinese PLA General Hospital, Beijing
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
NOT_YET_RECRUITING
Shandong Cancer Hospital, Jinan
NOT_YET_RECRUITING
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
NOT_YET_RECRUITING
West China Hospital of Sichuan University, Chengdu
NOT_YET_RECRUITING
First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Suzhou Immunofoco Biotechnology Co., Ltd
INDUSTRY